Loading...
DMTK.Q logo

DermTech, Inc.OTCPK:DMTK.Q 주식 보고서

시가총액 US$35.0
주가
US$0.000001
내 적정 가치
해당 없음
1Y-100.0%
7D-99.0%
1D
포트폴리오 가치
​
보기

DermTech, Inc.

OTCPK:DMTK.Q 주식 리포트

시가총액: US$35.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

DermTech (DMTK.Q) 주식 개요

분자 진단 회사인 DermTech는 미국에서 흑색종 진단 및 관리를 지원하는 새로운 비침습적 유전체학 테스트의 개발 및 마케팅을 담당하고 있습니다. 자세히 보기

DMTK.Q 펀더멘털 분석
스노우플레이크 점수
가치 평가2/6
미래 성장0/6
과거 실적0/6
재무 건전성3/6
배당0/6

강점

지난 1년간 수익이 9.7% 증가했습니다.

위험 분석

의미 있는 시가총액이 없습니다($35)

지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.

최신 재무 보고서가 1년 이상 지났습니다.


DMTK.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

DermTech, Inc. 경쟁사

가격 이력 및 성과

DermTech 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$0.000001
52주 최고가US$0.077
52주 최저가US$0.000001
베타29.95
1개월 변동-99.00%
3개월 변동0%
1년 변동-100.00%
3년 변동-100.00%
5년 변동-100.00%
IPO 이후 변동-100.00%

최근 뉴스 및 업데이트

분석 기사 • May 21

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 44% in the last...

Recent updates

분석 기사 • May 21

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 44% in the last...
분석 기사 • Mar 02

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 28% in the last...
분석 기사 • Dec 28

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

You may think that with a price-to-sales (or "P/S") ratio of 4.5x DermTech, Inc. ( NASDAQ:DMTK ) is definitely a stock...
분석 기사 • Sep 18

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Jun 14

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • May 10

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

One thing we could say about the analysts on DermTech, Inc. ( NASDAQ:DMTK ) - they aren't optimistic, having just made...
분석 기사 • May 06

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 37% in the last...
분석 기사 • Jan 16

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Nov 08

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

The latest analyst coverage could presage a bad day for DermTech, Inc. ( NASDAQ:DMTK ), with the analysts making...
분석 기사 • Oct 11

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 11

DermTech grants stock options

DermTech (NASDAQ:DMTK) granted one new, non-executive employee non-qualified stock options to buy ~38.78K common shares. The stock options, which have an exercise price of $4 per share, were granted under Inducement Equity Incentive Plan, the company said in an Oct. 10 press release.
Seeking Alpha • Sep 01

Diving Into DermTech

Summary Today, we take our first look at DermTech, Inc., a small molecular testing concern. The company is seeing some sales traction and the stock sells for less than cash value, but DermTech's cash burn rate is more than concerning. A full investment analysis of DermTech follows in the paragraphs below. Come friends, it's not too late to seek a newer world.”― Alfred Lord Tennyson Today, we put the spotlight on a small diagnostic firm called DermTech, Inc. (DMTK). This company has what it is a potential "best of breed" and non-invasive way to test for melanoma. Its core product is seeing some sales traction and the company currently has a lot of cash on the balance sheet. However, cash burn is a major concern around DermTech. An analysis follows below. Seeking Alpha Company Overview: DermTech, Inc. is a molecular testing concern based out of La Jolla, California. The company develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the U.S. The shares currently trade around $5.50 a share and sport an approximate market capitalization of $170 million. November 2021 Company Presentation The company's non-invasive tests to diagnose skin conditions that are more effective than traditional biopsy-based diagnostic tests. The company's main test right now is called the DermTech Smart Sticker. This replaces a scalpel to remove the skin cells off the surface of a mole. The DermTech Smart Sticker provides an accurate, non-invasive test to detect melanoma. November Company Presentation Second Quarter Results: On August 8th, the company posted second quarter numbers. DermTech had a GAAP loss of 99 cents a share, slightly better than the consensus. Revenues rose nearly 36% on a year-over-year. However, revenues were only $4.23 million, and that was somewhat under expectations. The company's net loss for the quarter widened to $29.6 million compared with a loss of $17.1 million in 2Q2021. Assay revenue increased by over 40% to $4.15 million while contract revenue declined some 60% to just to $86,000. Billable sample volume grew 56% to 18,320 compared to the same period a year ago. The company also saw a 67% increase in unique ordering clinicians to approximately 2,390. Thanks to continued acceptance, DermTech Smart Sticker is now available to approximately 91 million covered lives. This breaks down as nearly 68 million for Medicare and Medicare Advantage and 23 million for commercial payers, which largely comes today from the Blue Shields of California, Illinois and Texas. The stock got hit when management took down their full year assay revenue estimate to $16 million to $19 million from $22 million to $26 million previously. The company has streamlined the laboratory processes, which reduced the per unit cost of the DermTech Smart Sticker by 28% sequentially to $177 per, but the product is also seeing a lower average selling price, or ASP, which is a key reason for the downward sales guidance revision. ASP was under pressure due to Medicare billing code edits, which are expected to be improved in the coming quarters. The company is pushing the launch of their direct-to-consumer offering "Luminate" that assesses skin cancer risk to the first half of 2023 to conserve costs. Analyst Commentary & Balance Sheet: Since second quarter results came out, four analyst firms including BTIG and Oppenheimer have reiterated Buy ratings. However, all four analyst firms significantly cut their price targets on DermTech. Price targets now proffered range from $14 to $24 a share. Prior to price target revisions, price targets from these four analyst firms was in the $19 to $48 range. Approximately one out of eight shares are currently held short. Numerous insiders have been frequent, but mostly small, sellers of the stock in 2022. They have sold approximately $500,000 worth of equity in aggregate so far this year. The last insider purchases of DMTK were in February of 2020. The company ended the second quarter of this year with just north of $175 million worth of cash and marketable securities on its balance sheet. Leadership believes this is sufficient capital to fund its current operating plan through the first quarter of 2024 Verdict: The current analyst consensus has the company losing nearly four bucks a share in FY2022 even as revenues advance over 50% to some $18 million. Next year, revenue growth is expected to accelerate with the company doing some $30 in sales in FY2023. However, losses are expected to only come down around 10%.
분석 기사 • Aug 10

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

One of the biggest stories of last week was how DermTech, Inc. ( NASDAQ:DMTK ) shares plunged 33% in the week since its...
Seeking Alpha • Jun 13

DermTech: Approaching An All Or Nothing Moment

DermTech (DMTK) has transformative solutions that are more effective and accurate than traditional biopsy-based diagnostic approaches for detecting Skin Cancer. Commercialization of its proprietary SmartSticker solution has been slow, despite recent significant investments in the company’s salesforce. Although the company’s solutions have enormous potential and could drive the stock price significantly higher if successfully commercialized, recent management guidance for the next 12 months was soft. The future outcome for DMTK may be binary - either massive success driven by mass product adoption or a slow fade to oblivion based on failed commercialization.
분석 기사 • Jun 04

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 31

DermTech - Taking A Second Look At The Growth Thesis

DMTK’s SmartSticker solution is proprietary and has been shown to be more effective and accurate than traditional biopsy-based diagnostic approaches, but the company must further commercialize this offering. DMTK has made significant sales, marketing and infrastructure investments over the past 6 months, which should drive 2022 to be a record financial year for the company. Investors should approach this opportunity with caution while collecting more data on DMTK’s ability to grow sales. The longer-term opportunity remains if DMTK can execute on its core growth strategies.
Seeking Alpha • Dec 23

DermTech: Adoption Headwinds And Earnings Misses

DMTK has a skin cancer diagnostics test in the market. The company has repeatedly missed earnings, and this time, they also lowered guidance. This sort of steady depletion of shareholder value does not look good for future investments.

주주 수익률

DMTK.QUS BiotechsUS 시장
7D-99.0%1.2%1.0%
1Y-100.0%34.9%28.7%

수익률 대 산업: DMTK.Q은 지난 1년 동안 34.9%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.

수익률 대 시장: DMTK.Q은 지난 1년 동안 28.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.

주가 변동성

Is DMTK.Q's price volatile compared to industry and market?
DMTK.Q volatility
DMTK.Q Average Weekly Movement6,514.9%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

안정적인 주가: DMTK.Q의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.

시간에 따른 변동성: DMTK.Q의 주간 변동성은 지난 1년간 9178%에서 6515%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.

회사 소개

설립직원 수CEO웹사이트
n/a207n/awww.dermtech.com

분자 진단 회사인 DermTech는 미국에서 흑색종 진단 및 관리를 지원하는 새로운 비침습적 유전체학 테스트의 개발 및 마케팅에 종사하고 있습니다. 이 회사는 비흑색종 피부암 제품 개발을 위해 흑색종 검출을 향상시키는 혁신적인 비침습적 방법인 DermTech 멜라노마 테스트(DMT)를 제공합니다. 또한 메스를 사용하여 의심스러운 병변을 생검하는 표준 치료를 포함하여 비침습적으로 피부 샘플을 수집할 수 있는 DermTech 스마트 스티커를 제공합니다.

DermTech, Inc. 기초 지표 요약

DermTech의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
DMTK.Q 기초 통계
시가총액US$35.00
순이익 (TTM)-US$89.63m
매출 (TTM)US$15.66m
0.0x
주가매출비율(P/S)
0.0x
주가수익비율(P/E)

DMTK.Q는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
DMTK.Q 손익계산서 (TTM)
매출US$15.66m
매출원가US$14.33m
총이익US$1.33m
기타 비용US$90.96m
순이익-US$89.63m

최근 보고된 실적

Mar 31, 2024

다음 실적 발표일

해당 없음

주당순이익(EPS)-2.54
총이익률8.51%
순이익률-572.19%
부채/자본 비율0%

DMTK.Q의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2025/07/23 04:02
종가2025/07/23 00:00
수익2024/03/31
연간 수익2023/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

DermTech, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Sally YanchusBrookline Capital Markets
Mark MassaroBTIG
Alexander NowakCraig-Hallum Capital Group LLC